{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000018","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.465565+00:00","generated_at":"2026-05-15T08:26:24.157293+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%","bullets":["Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.","FDA BPD Type 2a meeting provided clear framework for remaining analytical comparability program; majority to be completed in 2026.","Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90%.","Appointed John Bencich as CFO; cash of $3.0M at Dec 31, 2025 plus $4.2M Jan PIPE proceeds expected to fund ops into Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000018","json":"https://secwatch.observer/filing/0001837607-26-000018.json","markdown":"https://secwatch.observer/filing/0001837607-26-000018.md","text":"https://secwatch.observer/filing/0001837607-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/0001837607-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/aeon-20260330x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:24.157293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f07b56db2101c0eec08957ca29c623e9e0bdd19b","claim":"AEON Biopharma, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/0001837607-26-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}